Novo Nordisk A/S (NEO:NVON)

Market Cap	249.47B -43.5%
Revenue (ttm)	66.62B +6.4%
Net Income	22.08B +1.4%
EPS	4.96 +1.8%
Shares Out	n/a
PE Ratio	11.30
Forward PE	12.45
Dividend	0.04 (0.99%)
Ex-Dividend Date	Mar 30, 2026

Volume	4,103
Average Volume	60,306
Open	4.180
Previous Close	4.170
Day's Range	4.150 - 4.180
52-Week Range	3.700 - 8.610
Beta	0.27
RSI	57.11
Earnings Date	May 6, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 69,150
• Stock Exchange: Cboe Canada
• Ticker Symbol: NVON

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK